Abstract
Alzheimer’s disease (AD) is characterized by three major histopathological hallmarks: β-amyloid deposits, neurofibrillary tangles and gliosis. While neglected for decades, the neuroinflammatory processes coordinated by microglia are now accepted as etiologic events in AD evolution. Microglial cells are found in close vicinity to amyloid plaques and display various activation phenotypes determined by the expression of a wide range of cytokines, chemokines, and innate immune surface receptors. During the development of AD pathology, microglia fail to restrict amyloid plaques and may contribute to neurotoxicity and cognitive deficit. Nevertheless, under specific activation states, microglia can participate in cerebral amyloid clearance. This review focuses on the complex relationship between microglia and Aβ pathology, and highlights both deleterious and beneficial roles of microglial activation states in the context of AD. A deeper understanding of microglial biology will hopefully pave the way for next-generation AD therapeutic approaches aimed at harnessing these enigmatic innate immune cells of the central nervous system.
Keywords: Alzheimer disease, amyloid-β peptide, chemokine, cytokine, gliosis, inflammation, innate immunity, microglia, neuroinflammation, phagocytosis.
CNS & Neurological Disorders - Drug Targets
Title:Innate Immunity in Alzheimer’s Disease: A Complex Affair
Volume: 12 Issue: 5
Author(s): Marie-Victoire Guillot-Sestier and Terrence Town
Affiliation:
Keywords: Alzheimer disease, amyloid-β peptide, chemokine, cytokine, gliosis, inflammation, innate immunity, microglia, neuroinflammation, phagocytosis.
Abstract: Alzheimer’s disease (AD) is characterized by three major histopathological hallmarks: β-amyloid deposits, neurofibrillary tangles and gliosis. While neglected for decades, the neuroinflammatory processes coordinated by microglia are now accepted as etiologic events in AD evolution. Microglial cells are found in close vicinity to amyloid plaques and display various activation phenotypes determined by the expression of a wide range of cytokines, chemokines, and innate immune surface receptors. During the development of AD pathology, microglia fail to restrict amyloid plaques and may contribute to neurotoxicity and cognitive deficit. Nevertheless, under specific activation states, microglia can participate in cerebral amyloid clearance. This review focuses on the complex relationship between microglia and Aβ pathology, and highlights both deleterious and beneficial roles of microglial activation states in the context of AD. A deeper understanding of microglial biology will hopefully pave the way for next-generation AD therapeutic approaches aimed at harnessing these enigmatic innate immune cells of the central nervous system.
Export Options
About this article
Cite this article as:
Guillot-Sestier Marie-Victoire and Town Terrence, Innate Immunity in Alzheimer’s Disease: A Complex Affair, CNS & Neurological Disorders - Drug Targets 2013; 12 (5) . https://dx.doi.org/10.2174/1871527311312050008
DOI https://dx.doi.org/10.2174/1871527311312050008 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Systems Biology of Apoptosis and Survival: Implications for Drug Development
Current Pharmaceutical Design Crystallization and Preliminary Crystallographic Analysis of Allograft Inflammatory Factor 1
Protein & Peptide Letters Peptide-Mediated Cellular Delivery of Oligonucleotide-Based Therapeutics In Vitro: Quantitative Evaluation of Overall Efficacy Employing Easy to Handle Reporter Systems
Current Pharmaceutical Design Editorial (Thematic Issue: Rational Design of Antiviral Compounds)
Current Pharmaceutical Design Hepatitis C Virus Proteins as Targets for Drug Development: The Role of Bioinformatics and Modelling
Current Drug Targets Editorial [Hot Topic: The Challenge of Viral Encephalitis: From Etiological Diagnosis to Efficient Antiviral Drug Discovery (Guest Editor: Laurent Dacheux)]
Infectious Disorders - Drug Targets Structural Disorder within the Measles Virus Nucleoprotein and Phosphoprotein
Protein & Peptide Letters Autism Spectrum Disorders: Etiology and Pharmacotherapy
Current Drug Therapy Are B Cells a Potential Target for Therapeutic Intervention in the Classical T Cell-Mediated Autoimmune Disease Type 1 Diabetes?
Inflammation & Allergy - Drug Targets (Discontinued) Clinical Applications of Intravenous Immunoglobulins in Child Neurology
Current Pharmaceutical Biotechnology Radiolabelled Molecules for Imaging the Translocator Protein (18 kDa) Using Positron Emission Tomography
Current Medicinal Chemistry Rift Valley Fever Virus
Current Molecular Medicine The Gut Mucosa as a Site for Induction of Regulatory T-Cells
Current Pharmaceutical Design Silybin and Silymarin - New and Emerging Applications in Medicine
Current Medicinal Chemistry Pharmaceutical Targeting of the Brain
Current Pharmaceutical Design Current Concepts on Selected Plant Secondary Metabolites With Promising Inhibitory Effects Against Enzymes Linked to Alzheimer’s Disease
Current Medicinal Chemistry Anti-Inflammatory Activity of Tetracyclines: Applications to Human Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Immunotherapy, Vascular Pathology, and Microhemorrhages in Transgenic Mice
CNS & Neurological Disorders - Drug Targets Infection and Anemia
Infectious Disorders - Drug Targets GEMSP: A New Therapeutic Approach to Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry